Targeting the Mitochondria in Heart Failure

Hani N. Sabbah, PhD

STATE-OF-THE-ART REVIEW

This article has been selected as this month’s JACC: Basic to Translational Science CME/MOC/ECME activity, available online at http://www.acc.org/jacc-journals-cme by selecting the JACC Journals CME/MOC/ECME tab.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the European Board for Accreditation in Cardiology (EBAC) to provide continuing medical education for physicians. The ACCF designates this Journal-based CME/MOC/ECME activity for a maximum of 1 AMA PRA Category 1 Credit ™ or 1 EBAC Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 AMA PRA Category 1 Credit ™ or 1 EBAC Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. The ACCF designates this Journal-based CME/MOC/ECME activity for a maximum of 1 AMA PRA Category 1 Credit ™ or 1 EBAC Credit.

Targeting the Mitochondria in Heart Failure: A Translational Perspective

A Translational Perspective

Upon completion of this activity, the learner should be able to: 1) identify the basic parameters measured in cardiopulmonary exercise testing; and 2) discuss the process of mitophagy.

CME/MOC/ECME Objective for This Article: Upon completion of this activity, the learner should be able to: 1) identify the basic parameters measured in cardiopulmonary exercise testing; and 2) discuss the process of mitophagy.

CME/MOC/ECME Editor Disclosure: CME/MOC/ECME Editor L. Kristin Newby, MD, is supported by research grants from Amylin, Bristol-Myers Squibb Company, GlaxoSmithKline, Sanoﬁ, Verily Life Sciences (formerly Google Life Sciences), the MURDOCK Study, NIH, and PCORI; receives consultative fees/honoraria from BioKier, DemeRx, Medscape/TheHeart.org, Metanomics, Philips Healthcare, Roche Diagnostics, CMAC Health Education & Research Institute; serves as an Ofﬁcer, Director, Trustee, or other fiduciary role for the AstraZeneca Healthcare Foundation and the Society of Chest Pain Centers (now part of ACC); and serves in another role for the American Heart Association and is the Deputy Editor of JACC: Basic to Translational Science.

Author Disclosures: Supported in part by research grants from Stealth BioTherapeutics, Inc. and National Heart Lung and Blood Institute (1RO1HL132154-01A1). Dr. Sabbah has received research grants from Stealth BioTherapeutics, Inc.; and is a consultant for Stealth BioTherapeutics, Inc. and Bayer AG.

Medium of Participation: Online (article and quiz).

CME/MOC/ECME Term of Approval

Issue Date: January 2020
Expiration Date: December 31, 2020

From the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan. Supported in part by research grants from Stealth BioTherapeutics, Inc. and National Heart Lung and Blood Institute (1RO1HL132154-01A1). Dr. Sabbah has received research grants from Stealth BioTherapeutics, Inc.; and is a consultant for Stealth BioTherapeutics, Inc. and Bayer AG. The author attests he is in compliance with human studies committees and animal welfare regulations of the author’s institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.

Manuscript received June 25, 2019; revised manuscript received July 19, 2019, accepted July 21, 2019.
Targeting the Mitochondria in Heart Failure
A Translational Perspective

Hani N. Sabbah, PhD

The burden of heart failure (HF) in terms of health care expenditures, hospitalizations, and mortality is substantial and growing. The failing heart has been described as "energy-deprived" and mitochondrial dysfunction is a driving force associated with this energy supply-demand imbalance. Existing HF therapies provide symptomatic and longevity benefit by reducing cardiac workload through heart rate reduction and reduction of preload and afterload but do not address the underlying causes of abnormal myocardial energetic nor directly target mitochondrial abnormalities. Numerous studies in animal models of HF as well as myocardial tissue from explanted failed human hearts have shown that the failing heart manifests abnormalities of mitochondrial structure, dynamics, and function that lead to a marked increase in the formation of damaging reactive oxygen species and a marked reduction in on demand adenosine triphosphate synthesis. Correcting mitochondrial dysfunction therefore offers considerable potential as a new therapeutic approach to improve overall cardiac function, quality of life, and survival for patients with HF. (J Am Coll Cardiol Basic Trans Science 2020;5:88-106) © 2020 The Author. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Mitochondria are intracellular double-membraned organelles that are considered the “power houses” of eukaryotic cells and, as such, are most abundant in cardiac muscle cells and in skeletal muscle type-1 fibers, where high-energy-requiring processes take place. The heart, being the most metabolically active organ in the body, possesses the highest content of mitochondria of any tissue (1), comprising about 25% of cell volume in human myocardium (2,3). The primary role of mitochondria is the generation of adenosine triphosphate (ATP) from adenosine diphosphate (ADP) using macromolecular complexes that form the electron transport chain (ETC): nicotinamide-adenine dinucleotide dehydrogenase (complex I [CI]), succinate dehydrogenase (CII), cytochrome bc1 (CIII), and cytochrome c oxidase (CIV) (4). Protons (H+) are pumped from the matrix to the intercristae space during these reactions, creating a proton gradient; ATP synthesis by the enzyme ATP synthase (CV) as a result of protons diffusing back along this gradient (Figure 1) (5,6). The coupling of substrate oxidation and ATP formation in the mitochondria (oxidative phosphorylation) is central to tissue and organ health (4). Cardiolipin is a key phospholipid expressed exclusively on the inner mitochondrial membrane that is required for ETC activity and is especially important for anchoring soluble cytochrome c to the inner mitochondrial membrane to facilitate electron transfer from CIII to CIV (7).

Humans produce and consume about 65 kg of ATP every day, with the heart accounting for about 8% of ATP consumption daily or about 6 kg (8). About 90% of cellular ATP within the myocardium is used to meet the enormous energy requirements for contraction and relaxation (both active processes and both ATP-dependent) (9). Mitochondrial dysfunction therefore plays a central role in a wide variety of metabolic and cardiac disorders, including heart failure (HF) (10). Dysfunctional mitochondria in skeletal muscle has been implicated in HF-associated exercise intolerance (11) and in the pathology of chronic metabolic disorders such as obesity and type 2 diabetes (12,13).

Because ATP cannot be stored, it is critical that the rate of ATP synthesis matches the rate of ATP consumption on a beat-to-beat basis (14). This process is accomplished by mitochondrial oxidative phosphorylation within the ETC using fatty acids as the primary fuel source (15). Although there are numerous reasons why a human heart can fail, the worsening of the HF state can be attributed, in part, to a mismatch between ATP supply and demand, also described as an engine “out of fuel” (8). Pathologic left ventricular (LV) remodeling including chamber dilation and hypertrophy causes inefficiencies that increase energy demand but concomitantly reduce the capacity for energy supply (Figure 2) (14). The subsequent altered bioenergetics attempt to regain energy homeostasis in the failing heart and are characterized by changes in substrate utilization, including an initial up-regulation and subsequent reduction of glucose utilization and a decrease in fatty acid utilization (14). Changes in oxidative phosphorylation are characterized by decreased energy production, with reductions in oxygen utilization, and respiratory-chain and ATP synthase activity. Changes in high-energy phosphate metabolism associated with HF include impaired creatine kinase energy-transfer mechanism, increased free ADP levels, and, in advanced HF, reduced ATP content (8). Mitochondrial dysfunction also contributes to skeletal muscle performance limitations by reducing the ability of the mitochondria to meet the ATP demand of aerobic, slow-twitch, fatigue-resistant working muscles (16). Lack of availability of energy at rest and during activity leads to progressive LV dysfunction and worsening of the HF state along with abnormalities of skeletal muscle composition that culminates in exercise intolerance.

Current treatments for chronic HF such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, and aldosterone antagonists rely primarily on energy-sparing maneuvers such as heart rate reduction and reductions of preload and afterload that help decrease overall cardiac workload for their therapeutic effect. Few strategies that can potentially increase ATP supply have emerged recently and are likely to undergo clinical assessment in the short term. The aim of this review is to describe the role and specific pathophysiologic mechanisms of mitochondria dysfunction in HF, as well as potential agents that target mitochondrial dysfunction in HF.

### Abnormalities of Mitochondria in the Failing Heart

**Ultrastructural Abnormalities.** It is well known that structural abnormalities of mitochondria in HF are present in animal models and in humans. These abnormalities include hyperplasia, reduced organelle size or fragmentation, and structural injury...
including loss of electron-dense matrix and disruption of inner and outer membranes (Figure 3) (17-19). In dogs with experimentally induced HF, there was a significant increase in the overall number of interbrillar mitochondria (hyperplasia) and a significant decrease in the overall average size of mitochondria relative to normal dogs (17), resulting in impaired mitochondrial respiratory activity (18). Abnormal mitochondrial morphology is also observed in cardiomyocytes of humans with HF (20-22). Human ischemic and idiopathic dilated cardiomyopathy are associated with functional mitochondrial abnormalities characterized by impaired respiration that can potentially adversely affect overall energy production and contribute to myocardial energy depletion (19).

In dogs with HF, mild to severe mitochondrial injury, ranging from electron-dense matrix depletion to myelinization, and mitochondrial membrane disruption, was observed in 27% of mitochondria compared with only 3% in normal dogs (p < 0.001) (17). Electron micrographs showed predominantly large mitochondria with tightly packed cristae and electron-dense matrix in cardiac tissue from normal dogs, whereas tissue from dogs with HF showed clearance of mitochondrial matrix and marked disorganization of mitochondrial cristae and severe mitochondrial injury including inner and outer membrane disruption and myelinization (17). Accordingly, the overall mitochondrial injury index (ratio of the number of injured mitochondria to the total number of mitochondria multiplied by the average score of the injury) was significantly higher in dogs with HF versus normal dogs. The extent of mitochondrial injury and injury index was similar across all the regions of the heart assessed (LV free wall, interventricular septum, and right ventricular free wall), and also correlated with increased plasma norepinephrine, suggesting a role for sympathoadrenergic hyperactivity in mitochondrial dysfunction in HF (17).

Mitofilin, an inner mitochondrial membrane structural protein, maintains cristae morphology and structure. Down-regulation of mitofilin in HeLa cells using specific small interfering ribonucleic acid resulted in mitochondria with abnormal morphology characterized by disorganized inner membranes, increased apoptosis, elevated reactive oxygen species
(ROS) production, and overall loss of mitochondrial function and structure (22). MiTofilin levels were also reported to be significantly reduced in LV tissues from explanted failed human hearts of both ischemic and idiopathic dilated cardiomyopathic etiologies compared with normal donor hearts (24).

Cardiolipin, a key phospholipid located in the inner mitochondrial membrane, is required to support energy production. It functions as a cofactor for mitochondrial transport proteins, including stabilization of supercomplexes (CI, CIII, CIV, and CV) and mitochondrial cristae and retention of cytochrome c to the inner mitochondrial membrane (25,26). Cytochrome c is a key electron carrier for electron transport and also triggers cellular apoptosis when released from mitochondria into the cellular cytoplasm. Peroxidation of cardiolipin leads to the release of cytochrome c into the cytoplasm, a process that triggers cellular apoptosis by activation of caspase-3 (27,28). Loss of cardiolipin in HF amplifies the production of ROS, which, in turn, aggravates the peroxidation of cardiolipin. This vicious cycle leads to further mitochondrial dysfunction and ultimately to cardiomyocyte death (26). Cardiolipin is also a key regulator of mitochondrial biogenesis and fission and fusion dynamics. In dogs with HF, compared with normal dogs, cardiolipin synthase-1, a key enzyme in the synthesis of cardiolipin was significantly reduced (29). The same study in dogs with HF also showed that the cardiolipin remodeling enzymes tafazzin-1 (TAZ-1) and acyl-CoA:lysocardiolipin acyltransferase-1 are dysregulated in HF. Specifically, TAZ-1 was significantly reduced and acyl-CoA:lysocardiolipin acyltransferase-1 was significantly increased in dogs with HF compared with normal dogs (29). It is well known that certain diseases arise from genetic mutations that adversely impact the ability of cardiolipin to perform key functional processes. Barth syndrome, for example, is caused by genetic mutations of TAZ-1 and is clinically manifested as cardiomyopathy, skeletal myopathy, neutropenia, and
growth retardation (25). Cardiolipin deficiency has been observed in both animal models of HF and in explanted failed human hearts (30–32). Gene expression of TAZ-1 and cytidine diphosphate-diacylglycerol synthetase-2, a rate-limiting enzyme in cardiolipin biosynthesis, were shown to be significantly reduced in failing relative to nonfailing human hearts (30).

**ABNORMALITIES OF MITOCHONDRIAL DYNAMICS.** Mitochondria have their own deoxyribonucleic acid (mtDNA) with a genetic code that is distinct from the host-cellular DNA. Mutations in mtDNA cause a variety of disorders characterized by altered energy homeostasis (reduced ATP synthesis) in high-energy tissues such as cardiac muscle. Mitochondrial turnover or biogenesis and respiration in both skeletal and cardiac muscle are regulated by the transcriptional factor peroxisome proliferator-activated receptor coactivator (PGC)-1α and PGC-1β (33,34). Expression of these key regulators of energy metabolism is reduced in animal

**FIGURE 3** LV Mitochondria in Normal Dogs and Dogs With HF

Transmission electron micrographs of left ventricular (LV) mitochondria in normal dogs and dogs with heart failure (HF). (Top left) Normal dog showing predominantly normal, large mitochondria with tightly packed cristae and electron-dense matrix, with insert depicting various structural components of mitochondria. (Top right) Coronary microembolization-induced HF showing mild abnormalities of mitochondria in the form of clearance of electron-dense matrix. (Bottom left) Coronary microembolization-induced HF showing moderate abnormalities of mitochondria in the form of reduced organelle size and marked disorganization of cristae. (Bottom right) Coronary microembolization-induced HF showing severe mitochondrial injury with inner and outer membrane disruption and myelinization. ID = intercalated disk; M = mitochondrion. Reprinted with permission from Sabbah (6) and adapted with permission from Sabbah et al. (17).
models of HF (35-38). PGC-1α was significantly down-regulated in LV myocardium of dogs with HF, and phosphorylation was markedly reduced, a dysregulation suggestive of abnormal biogenesis (39). Patients with HF of diverse etiologies also showed reductions in mtDNA contents accompanied by reductions in mtDNA-encoded proteins. Impaired mitochondrial biogenesis was also reported in failing human hearts, which is possibly the result of defective mtDNA replication (40). Down-regulation of estrogen-related receptor α is required for the activation of mitochondrial genes and increased mitochondrial biogenesis was also observed as well as reduced expression of a number of mitochondrial genes under transcriptional control of estrogen-related receptor α. DNA microarray alterations in PGC-1α and estrogen-related receptor α target gene sets correlated with LV ejection fraction and predicted failing versus nonfailing genetic phenotypes (41). The observations overall suggest that mitochondrial biogenesis signaling is reduced in HF and implicate the transcriptional energy metabolic regulator PGC-1α and its target genes in the pathogenesis of this maladaptation.

**Mitochondrial fusion and fission.** The dynamic physiological process of mitochondrial biogenesis is governed, in part, by fusion and fission of the organelles (Figure 4) (24). Mitochondria undergo fusion to form elongated interconnected mitochondrial networks and fission to produce discrete fragmented mitochondria (42). These processes, both regulated by specific mitochondrial fission and fusion proteins, ensure maintenance of mtDNA integrity by eliminating mitochondria with damaged DNA and promoting functional mtDNA content (6). Mitochondrial fission is facilitated by dynamin-related protein
(Drp)-1 and fission (Fis)-1 and ensures equal division of mitochondrial numbers during cell division and mediates removal of damaged mitochondria (mitophagy) (29,43). Mitochondrial fusion, mediated primarily by mitofusin (Mfn)-2 in the outer membrane and by optic atrophy (OPA)-1 in the inner membrane, allows mixing of intra-mitochondrial proteins and replacement of damaged mtDNA (29,43). Fusion maintains the structural integrity of the inner mitochondrial membrane and matrix, preserving oxidative phosphorylation and avoiding formation of cytotoxic oxidizing molecules generated via interruption of the ETC (43). In animal models of HF, Mfn-1 and Mfn-2 ablation results in a lethal cardiomyopathy (44,45), whereas a reduction of OPA-1 expression with short hairpin ribonucleic acid results in increased apoptosis and fragmentation of the mitochondria and overexpression of OPA-1 that results in increased mitochondrial tubularity (46). Mfn-1 or OPA-1 ablation induces LV hypertrophy (47,48). In LV myocardium of dogs with chronic HF, Mfn-2 and OPA-1 were significantly down-regulated whereas...
Drp-1 and fission-1 were significantly up-regulated, indicating a marked dysregulation of fission and fusion dynamics (Figure 4) (24). Measures of mitochondrial dynamics in humans with HF (LV tissue from 12 explanted failing human hearts, 6 each failing due to ischemic and nonischemic etiologies, with comparisons made with LV tissue from 6 normal donor hearts) were consistent with those observed in dogs with experimentally induced HF (24). PGC-1α protein levels were significantly lower in the failing hearts (both etiologies) relative to the healthy donor hearts, and a marked dysregulation in the mitochondrial fission and fusion proteins (fission-1 and Drp-1 were significantly increased and Mfn-2 and OPA-1 were significantly decreased), and of the mitochondrial inner membrane protein mitofilin (which was significantly decreased) (24).

Mitophagy. Mitophagy is a central step in maintaining the mitochondrial quality control process and overall health of the cellular mitochondrial pool by removing mitochondria with damage too severe for correction through biogenic or fusion-mediated repair (Figure 5) (49). Mitochondrial fission suppression accelerates mitophagy by lowering the threshold for mitochondrial removal, a maladaptation likely to promote the elimination of functioning mitochondria, whereas mitochondrial fusion inhibition suppresses mitophagy, thus reducing the removal of toxic, ROS-producing mitochondria. Studies in mitochondrial fission- and fusion-defective murine hearts and cells showed that Drp-1-mediated mitochondrial fission is essential to properly target mitophagy and restrain mitochondrial permeability transition pore (MPTP)-mediated cell necrosis (50). Mfn-1 and/or Mfn-2 deletion caused accumulation of defective mitochondria without appropriately increasing mitophagy, whereas Drp-1 ablation interrupted mitophagy, causing a generalized loss of mitochondria (50). MPTP opening in Drp-1-null mitochondria was associated with mitophagy, cardiomyocyte necrosis, and dilated cardiomyopathy (50). As eluded to earlier, reduced
myocardial levels of fusion-regulating proteins and increased levels of fission-regulating proteins are present in LV myocardium of dogs and humans with HF (29,51). These observations underscore the importance of the ability of mitochondria in the myocardium to serially execute fission and fusion followed by mitophagy, which is essential for maintenance of mitochondrial health and survival.

Abnormalities of mitochondria occur in cardiomyocytes of the failing heart and, as mentioned earlier, include hyperplasia, reduced organelle size, and disruption of the inner membrane. The underlying causes of these abnormalities are not fully understood but are believed to result from abnormalities associated with mitochondrial fission, fusion, and mitophagy. The selective degradation of mitochondria is an essential process for mitochondrial quality control in both health and disease (49). When mitochondria are normal, phosphatase and tensin homolog-inducible kinase (PINK)-1 is imported into the mitochondria via the translocase of the outer membrane–translocase of the inner membrane import

FIGURE 7 Measures of Mitochondrial Function

(Left) Bar graphs depicting total cardiolipin level (CL) normalized to mitochondrial (MITO) protein (top), total (18:2) CL normalized to MITO protein level (middle), and MITO complex IV activity (bottom) in left ventricular myocardium of NL dogs, untreated HF control dogs (HF-CON), and dogs with HF treated with elamipretide (HF + ELA). (Right) MITO states 3 and 4 respiration (top), MITO membrane potential (middle), and maximum rate of ATP synthesis (bottom) in left ventricular myocardium of NL dogs, untreated HF-CON dogs, and HF + ELA dogs. All bar graphs are depicted as mean ± SEM. Adapted with permission from Sabbah et al. (57). ADP = adenosine diphosphate; RLU = relative light units.
complex where it is cleaved by presenilin-associated rhomboid-like protein (Figure 5). Cleaved PINK-1 is then retro-translocated to the cytosol and degraded by proteasome (49). However, when mitochondria are damaged, import of PINK-1 is terminated and the protein accumulates on the outer mitochondrial membrane. PINK-1 is then phosphorylated by adenosine monophosphate-activated protein kinase α-2. Phosphorylated PINK-1 recruits the E3 ubiquitin ligase Parkin to the mitochondria from the cytosol. PINK-1 phosphorylates both Parkin- and Mfn-2-promoting ubiquitination of mitochondrial substrates (49,52). The valosin-containing protein transports ubiquinated mitochondria to the mitophagosomes for their degradation (Figure 5) (49,53). In HF, this pathway is dysregulated, resulting in partial deactivation of mitophagy and, hence, the accumulation of damaged mitochondria. Recent studies in sodium dodecyl sulfate-extracts of LV tissue, extracts of mitochondria isolated from LV tissue, as well as cytosolic fractions of LV tissue of dogs with HF, showed significant down-regulation of PINK-1, adenosine monophosphate-activated protein kinase α-2, phosphorylated Mfn-2, Parkin, and valosin-containing protein in HF dogs compared with in normal dogs (F. Last, unpublished observations, April 2019) (Figure 6).

MITOCHONDRIAL FUNCTIONAL ABNORMALITIES. Mitochondria in the failing heart also manifest functional abnormalities highlighted by excessive production of ROS with reduced ATP production (18,19,54). Studies conducted in dogs with chronic HF showed significant reductions in mitochondrial membrane potential, maximum rate of ATP synthesis, ATP-ADP ratio, and of 18:2 cardiolipin (a key
structural lipid of the inner mitochondrial membrane on which the mitochondrial ETC resides), and a significant increase in cytochrome c in cardiomyocyte cytosolic fraction (55,56). Measures of key subunits of mitochondrial complexes showed that CI and CIV activities were also significantly reduced in dogs with HF relative to normal control animals (57).

Increased opening of the MPTP, decreased mitochondrial membrane potential, and decreased mitochondrial cytochrome c oxidase and state-3 mitochondrial membrane potential, and decreased mitochondrial cytochrome c oxidase, improved mitochondrial cytochrome c oxidase-dependant respiration, and tended to enhance the maximum rate of ATP synthesis (55,56).

Mitochondrial ROS production is dependent on the mitochondrial membrane potential. The combination of ROS with elevated calcium concentrations leads to MPTP opening and subsequently reduced membrane potential, which decreases the extramitochondrial phosphorylation potential, adversely impacting cell function (58,59); a surge in ROS production leads to cytochrome c release, which initiates cell death via apoptosis (60,61). Mitochondrial damage to cardiomyocytes from excess ROS production limits ATP production to a level insufficient to support the H+ pump function during times of high oxidative energy requirements (62).

Mitochondrial production of ROS occurs at sites along the inner mitochondrial membrane by ETC components and in the mitochondrial matrix by components of the Krebs cycle (63). Under normal physiological conditions, ROS production is typically low and is maintained by intracellular and intramitochondrial scavenging systems. Pathological ROS levels in the heart typically occur with excessive ROS production and reduced endogenous scavenging capacity, leading to protein and lipid damage, cell death cascades, and synchronized breakdowns in the cellular energy grid (64,65). ROS can damage the mitochondrial ETC (66), trigger lipid peroxidation (67), oxidize proteins (68), and cause DNA strand breaks (69), all of which can lead to mitochondrial dysfunction (70). Elevated mitochondrial ROS production and downstream ROS-mediated damage; mtDNA damage; decreased enzymatic activity of CI, CIII, and CIV; and defects in electron transport function have been reported in animal models of HF (71-73).

**ABNORMALITIES OF SKELETAL MUSCLE IN HEART FAILURE AND ROLE OF MITOCHONDRIA**

**FIBER TYPE COMPOSITION.** Exercise intolerance is a hallmark of chronic HF. Observations of a poor correlation between central hemodynamics and exercise intolerance in patients with HF shifted interest to peripheral factors, including skeletal muscle structure and metabolism (74-79). Exercise intolerance in HF has been attributed to skeletal muscle atrophy, a shift from slow-twitch type 1 (oxidative) to fast-twitch type 2 (glycolytic) muscle fibers, mitochondrial abnormalities, and increased inducible nitric oxide synthase expression with resulting increase of nitric oxide and causing a decrease in mitochondrial creatine kinase, a key enzyme necessary for the transfer of high-energy phosphates from mitochondria to cytosol (80-84). A decrease in the relative composition of type-1 fibers and an increase in type-2 fibers has been shown in dogs with coronary microembolization-induced HF (83). This shift from type-1 to type-2 muscle fibers was associated with reduced exercise tolerance but not with atrophy of either fiber type (83).

The changes in composition of skeletal muscle fiber type are have also been described in patients with HF and are also associated with exercise intolerance (77,81,85). Patients with chronic HF have a reduced proportion of slow twitch type-1 fibers and a higher proportion of type-2 fast twitch fibers in vastus lateralis skeletal muscle biopsies (74,77). These patients also manifest a reduction in myosin heavy-chain type I (85), an isoform that is more abundant in skeletal muscle type-1 aerobic fibers. In HF, the shift in fiber-type composition may be partly due to skeletal muscle mitochondrial abnormalities and the associated reduction of ATP synthesis needed by aerobic type-1 fibers (86); reduction in ATP production can lead to an adaptation of slow-twitch type-1 fibers to utilize glycogen as energy source and thus shifting fiber-type composition toward a fast-twitch phenotype.

**MITOCHONDRIAL ABNORMALITIES IN SKELETAL MUSCLE.** Under normal physiologic conditions, ATP production by oxidative phosphorylation in the mitochondria fulfills most of the ATP demands of skeletal muscle at rest and during exercise (16). Mitochondrial dysfunction, therefore, can contribute to decrements in skeletal muscle performance via loss of mitochondrial capacity to generate ATP, or reduced ability to meet ATP demand of working skeletal muscle.
Studies using skeletal muscle biopsies obtained from the leg vastus lateralis muscle showed marked functional abnormalities of mitochondria in dogs with coronary microembolization-induced HF compared with normal dogs (11). Mitochondria from skeletal muscle of HF dogs showed significant reductions in ADP-stimulated respiration, membrane potential, and CIV activity compared with skeletal muscle from normal dogs (11). Levels of inducible nitric oxide synthase were also significantly increased in HF dogs compared with in normal dogs (11). In this same study, measurements of cytochrome c and HtrA serine peptidase-2, a proapoptotic mitochondrial serine protease involved in caspase-dependent and caspase-independent cell death, in isolated mitochondria showed a decrease of cytochrome c and HtrA serine peptidase-2 in HF-control dogs compared with normal dogs, indicating translocation of cytochrome c and HtrA serine peptidase-2 from the mitochondria to the cytosol, the latter is a known trigger for activation of caspase-3-dependent and caspase-3-independent apoptotic pathways (11).

A variety of alterations specific to skeletal muscle, including muscle atrophy, myocyte apoptosis, fiber-type changes, defects in oxidative metabolism, and decreased mitochondrial volume density have been described in patients with HF (87). Studies using phosphorus P 31 nuclear magnetic resonance spectroscopy clearly demonstrated intrinsic skeletal muscle metabolic abnormalities in patients with chronic HF (74). These metabolic abnormalities likely contribute to skeletal muscle contractile dysfunction and, consequently, to the reduced exercise capacity observed in patients with HF.

**AGING MITOCHONDRIA AS A MODEL OF MITOCHONDRIAL ABNORMALITIES IN HEART FAILURE**

The majority of patients with chronic HF are 65 years of age or older. This is particularly true for patients with heart failure with preserved ejection fraction (HFpEF) whose average age is well into the 70s. Mitochondria are important regulators of the aging process, and abnormalities in mitochondrial quality control, including biogenesis and mitophagy, are considered a major driver of cellular senescence with aging. Replicative and degradative processes continually turn over mtDNA within the mitochondrial matrix. The incidence and frequency of mtDNA mutations increase markedly with age, contributing to cellular senescence (88,89). In mice expressing error-prone mtDNA polymerase γ defective for proof-reading activity (which causes increased mutation frequency), loss of function of DNA proofreading activity produced faulty respiratory chain proteins and premature aging (90–92). In addition, in transgenic mice, these mitochondrial defects (rapid accumulation of mtDNA mutations) caused premature aging, dilated cardiac hypertrophy, and death by congestive HF within 6 months (93). Fusion of healthy mitochondria with mitochondria possessing mtDNA mutations during replication can have an impact on the quality of the mitochondrial pool within the cell (94–96). As the age-related accumulation of somatic mtDNA mutations increases, mitochondrial function is eroded (i.e., mitochondrial energetic output declines, ROS production increases, as does the propensity for apoptosis), cells are progressively lost through apoptosis and organ function declines, which ultimately leads to symptoms when the number of cells in a given organ declines below the minimum necessary to maintain normal function (97).

Mitochondrial efficiency and capacity to generate ATP in skeletal muscle is particularly susceptible to advancing age. The theoretical maximum capacity for mitochondrial ATP production and mitochondrial volume density in the human quadriceps are reduced in sedentary versus active subjects, as is the flux per mitochondrial volume, indicating that the observed capacity loss is due to both reduced mitochondrial content and quality (98). Mitochondrial respiratory capacity and coupling control of skeletal muscle mitochondria also decline with advancing age; specifically, respiratory capacity and the proportion of respiration coupled to phosphorylation are lower in older adults (99). These findings suggest that the capacity of skeletal muscle mitochondria to produce electrochemical potential and to couple this to ADP phosphorylation is diminished with advancing age (99).

In addition to loss of mitochondrial capacity, mitochondrial quality is reduced in aged skeletal muscle. Coupling of oxidative phosphorylation declines with age in human (100) and mouse (86,101,102) skeletal muscles. Reduced coupling of oxidative phosphorylation was also observed in young sedentary adults compared with age-matched control subjects, supporting a vital role for physical activity in the maintenance of mitochondrial quality (103). In aging skeletal muscle, controllers of skeletal muscle biogenesis and quality are disrupted, especially PGC-1α, a key regulator of mitochondrial biogenesis (104–106). Age-related declines in PGC-1α expression in skeletal muscle have been demonstrated in human and rodent models (107–110). Deterioration in mitochondrial quality control is another important aspect of aging and HF on mitochondrial
dysfunction in skeletal muscle. The efficiency of mitophagy in skeletal muscle is impaired with age (111–113).

**POTENTIAL THERAPEUTIC INTERVENTIONS**

A number of therapeutic breakthroughs in the treatment of HF have substantially improved patient outcomes; however, there have been few breakthroughs in HF treatment over the past decade. The current treatment paradigm for patients with heart failure with reduced ejection fraction (HFrEF) involves systemic blockade of maladaptive neurohumoral systems to attenuate progressive cardiac remodeling and improve clinical outcomes. Nearly all of these treatments have relied on reducing cardiac workload through a decrease in heart rate, preload, and afterload. The concurrent hemodynamic effects of these therapies such as bradycardia and decreased preload and/or afterload limit the achievement of optimal therapy intensity in some patients and rarely achieve improvements in quality-of-life indicators such as an improvement in exercise tolerance. Furthermore, existing therapies provide symptom relief and clinical benefit but do not adequately address the molecular abnormalities of HF, underscoring the unmet need to develop more effective and complimentary therapy for these patients, including treatments that target myocardial and skeletal muscle energetics through modulation of mitochondrial function in the failing heart. What follows is a brief description of some novel therapies that seek to derive benefits in the treatment of HF by targeting or partially targeting the mitochondria.

**ELAMIPRETIDE.** Elamipretide (SS-31, MTP-131, Bendavia, Stealth BioTherapeutics, Newton, Massachusetts) is a water-soluble, aromatic-cationic mitochondria-targeting tetrapeptide that readily penetrates and transiently localizes to the inner mitochondrial membrane and associates with cardiolipin to restore mitochondrial bioenergetics (7,114). As discussed, mitochondrial cardiolipin is essential for the proper assembly and stability of the ETC to ensure optimal mitochondrial function, including biogenesis, fusion and fission, respiration, regulation of cristae formation, mtDNA stability and segregation, protein import, as well as the function and organization of the respiratory complexes into supercomplexes for oxidative phosphorylation (25,115,116).

Studies in dogs with coronary microembolization-induced chronic HF showed that 3 months’ treatment with daily subcutaneous injections of elamipretide improved LV systolic function and prevented progressive LV dilation without affecting heart rate, blood pressure, or systemic vascular resistance (57). Elamipretide also elicited a normalization of mitochondrial function evidenced by improved respiration, normalization of membrane potential, reduced ROS formation, and improved maximum rate of ATP synthesis (Figure 7) (57). These improvements were accompanied by reduction of plasma biomarkers of N-terminal pro-B-type natriuretic peptide and proinflammatory cytokines including tumor necrosis factor-α, interleukin-6, and C-reactive protein. In LV tissue obtained from these dogs, chronic therapy with elamipretide reversed the dysregulation of mitochondrial fission (fission-1 and Drp-1) and fusion (Mfn-2 and OPA-1) proteins and PGC-1α protein levels, supporting observations of improved mitochondrial respiration, maximum rate of ATP synthesis, and LV function (51). The dysregulation in cardiolipin and determinants of cardiolipin synthesis and remodeling, including cardiolipin synthase-1, TAZ-1, and acyl-CoA:lysocardiophosphatidyl acyltransferase-1 were also normalized after 3 months’ therapy with elamipretide (24).

Long-term treatment with elamipretide also restored skeletal muscle fiber-type composition to a more normal distribution (increased proportion of skeletal muscle type-1 fibers relative to skeletal muscle type-2 fibers) in dogs with HF. Elamipretide also improved mitochondrial function in skeletal muscle myofibers isolated from dogs with chronic HF and reduced levels of inducible nitric oxide synthase (11), changes that would be expected to lead to improved exercise tolerance (81). In a recent study, elamipretide treatment rapidly improved mitochondrial oxygen flux, CI and CIV activities, and supercomplex-associated CIV activity in freshly explanted failing ventricular tissue from children and adults (112). These effects were independent of cardiolipin remodeling and suggest that the improvement in mitochondrial function was likely mediated through improved coupling of the mitochondrial supercomplex.

A phase 1/2 ascending single-dose study of elamipretide (4-h infusions of 0.005, 0.05, and 0.25 mg/kg/h) in 36 patients with HFrEF showed that elamipretide was well tolerated and significantly reduced LV end-diastolic (-18 ml; p = 0.009) and end-systolic (-14 ml; p = 0.005) volumes in the highest dose cohort (118). No serious adverse events were reported in any of the cohorts and blood pressure and heart rate remained stable. Two phase 2 clinical trials
examining the effects of elamipretide in patients with HFrEF (The Effect of Multiple Injections of Elamipretide on Various Measures of Heart Function in Patients With Chronic Heart Failure With a Reduced Ejection Fraction; NCT02788747) and in patients with HFrEF (A Study to Evaluate the Effects of 4 Weeks’ Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction; NCT02814097) are underway.

**PARTIAL ADENOSINE A1 RECEPTOR AGONISTS.**

Adenosine is a purine nucleoside that exerts a variety of physiological actions by binding to adenosine cell surface receptor subtypes A1, A2a, A2b, and A3, acting as a cytoprotective modulator that links cardiac function to metabolic demand (119). The cardioprotective effects of adenosine are primarily mediated by activation of the A1 receptor subtype (120,121). Potential ways that adenosine A1 receptor activation might improve HF include enhancement of cardiomyocyte energetics, calcium homeostasis, and cardiac structure and function (119). Adenosine A1 receptor activation results in downstream inhibition of adenylyl cyclase and reduction in intracellular levels of cyclic adenosine monophosphate (122), promoting a cardioprotective state by reducing sympathetic overactivation and enhancing atrial natriuretic peptide release (123,124). Adenosine A1 receptors also modulate mitochondrial K<sub>ATP</sub> channels via activation of protein kinase C, which reduces mitochondrial protein transition pore opening, improving mitochondrial function under hypoxic conditions (125). Activation of the adenosine A1 receptor using the selective agonist N6-cyclopentyladenosine similarly prevented phenylephrine-mediated cardiomyocyte hypertrophy and cardiac fibrosis, and upregulated adenosine A1 receptor expression in a rat model of compensated hypertrophy (126). The results suggest that adenosine A1 receptor agonism might mitigate α1-adrenoeceptor-stimulated cardiac remodeling and subsequent cardiac dysfunction (126).

Activation of adenosine A1 receptors using full agonists is limited by adverse effects, including bradycardia, atrioventricular block, vasodistortion, negative inotropy and dromotropy, sedation, and antidiuretic effects (127,128). These undesirable effects can be overcome by the use of partial A1 receptor agonists (129). The benefits of partial adenosine A1 receptor agonists for the treatment of HF, therefore, lie in their ability to protect the failing myocardium by limiting triggers of cell injury and death and potentially by providing the necessary energy to the working myocardium (130).

In dogs with microembolization-induced chronic systolic HF, 12 weeks of therapy with oral capadenoson, a partial adenosine A1 receptor agonist, improved LV systolic function and prevented progressive LV enlargement, as evidenced by an improvement in LV ejection fraction and a reduction of LV end-systolic volume (130). Treatment with capadenoson also significantly decreased plasma norepinephrine and plasma N-terminal pro-B-type natriuretic peptide. Histomorphometric findings showed that capadenoson significantly decreased volume fraction of interstitial fibrosis, oxygen diffusion distance, and myocyte cross-sectional area and increased capillary density (124). Capadenoson also normalized expression of mitochondrial uncoupling proteins-2 and -3, mitochondrial citrate synthase, and sarcoplasmic reticulum calcium ATPase-2a activity (Figure 8) (130). Capadenoson treatment did not induce bradycardia or lower systemic blood pressure.

Issues with central adverse effects of vertigo and dizziness observed with capadenoson in a clinical trial in patients with stable angina pectoris (suggesting that the degree of adenosine A1 receptor agonism was too high) (131), as well as low solubility, which hampered tablet development (132), led to the identification and development of neladenoson bialanate (Bay1067197, Bayer HealthCare Pharmaceuticals, Montville, New Jersey), a prodrug currently being evaluated in clinical trials for the treatment of HF (132). In 2 small pilot trials in patients with HFrEF, oral neladenoson bialanate treatment was well tolerated and no atrioventricular conduction disorders or neurological adverse effects were observed (133). In the first study that assessed single-dose neladenoson bialanate 30 mg in 11 patients receiving background beta-blocker therapy, the drug was well tolerated and no second- or third-degree atrioventricular block was detected on 48-h ambulatory electrocardiographic monitoring (133). In the second study, the double-blind, placebo-controlled PARSiFAL (Partial Adenosine Receptor Agonist in Heart Failure) study, 7 days’ treatment with either 10 mg or 20 mg daily in 31 patients receiving optimal HF therapy (all patients were receiving beta-blockers) was also well tolerated and no episodes of second- or third-degree atrioventricular block, detrimental effects on heart rate or blood pressure, or clinically relevant neurological adverse effects were observed (133). There was no significant difference, however, in ejection fraction among study groups. Two phase 2 dose-finding trials, PANTHEON (A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction; NCT02992288) and PANACHE (A Trial to Study Neladenoson Bialanate
Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction; NCT03098979), are underway to assess the efficacy and safety of nela-
denoson bialanate (dose range 5 to 40 mg/day) in patients with HFrEF and HFpEF, respectively (134).

CONCLUSIONS

The burden of HF in terms of health care expendi-
tures, hospitalizations, and mortality is growing in the United States and worldwide and will likely continue to increase with the aging of the population (1,6). Current therapies for HF produce benefit by reducing cardiac workload by lowering heart rate and loading conditions, which reduces myocardial energy demands. The recent recognition that the failing heart is “energy deprived” and that mitochondrial dysfunction is a driving force associated with this energy imbalance in the heart has led to the evaluation of mitochondria as therapeutic target in HF. Mitochondrial dysfunction in the heart leads to reduced ATP synthesis and excessive formation of damaging ROS. In this review, we have described abnormalities of mitochondrial structure, function, and dynamics in the failing heart and briefly discussed studies of novel agents that target or partially target mitochondrial dysfunction in HF. The structural, dynamic, and functional abnormalities described herein, coupled with excessive ROS production, are undoubtedly instrumental in mediating progressive mitochondrial cellular injury and dysfunction that culminate in progressive worsening of HF. Correcting mitochondrial dysfunction to enhance the energy supply of the failing heart to meet the desired energy needs offers considerable potential to improve cardiac function, reduce symp-
toms, and improve exercise tolerance in HF, and ultimately offer improved quality of life and survival for patients, and reduce the overall economic burden of this condition.

TRANSLATIONAL OUTLOOK. Although our understanding of mitochondrial dysfunction in HF has markedly improved over the past several years, application of this newly gained knowledge toward the development of drugs that target mitochondrial dysfunction in HF remains in its early stages. Questions remain as to what particular aspects of mitochondrial dysfunction should be targeted, such as biogenesis, mitophagy, fission, and fusion, or the ETC complexes that are likely to yield the best outcomes. Another issue is the conditions under which the therapy is applied and likely to lead to a positive outcome in a given HF patient population. Should one expect improvements under resting conditions or, more likely, during exercise when energy de-
mands on mitochondria are highest? Outcomes may vary depending on the stage of the disease and its form (HFrEF or HFpEF). Answers to these and many other questions will be helpful in developing target-
specific drugs and in designing appropriate clinical trials.

ACKNOWLEDGMENTS The author thanks Rick Davis, RPh, and Jim Shiffer, RPh, CCP, for their assistance in the preparation of this manuscript.

ADDRESS FOR CORRESPONDENCE: Dr. Hani N. Sabbah, Henry Ford Health System, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202. E-mail: hsabbah1@hfhs.org.
Targeting Mitochondria in Heart Failure

17. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1992;24:1333–42.

18. Sharov VG, Goussav A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998;30:1757–62.

19. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochondrial respiration in failed human myocardium. J Mol Cell Cardiol 2000;32:2361–7.

20. Baandrup U, Florio RA, Roters F, Olsen EG. Electron microscopic investigation of endomyocardial biopsy samples in hypertrophy and cardiomyopathy: a semiquantitative study in 48 patients. Circulation 1981;63:1289–98.

21. Ferrans VJ, Morrow AG, Roberts WC. Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis: a study of operatively excised left ventricular outflow tract muscle in 14 patients. Circulation 1972;45:769–92.

22. Peronen J, Hatt P. Myocardial morphology in cardiac hypertrophy and failure: electron microscopy in man. In: Swynghedauw B, editor. Cardiac histology. New York: Libbey and Company, 1988:267–76.

23. John GB, Shang Y, Li L, et al. The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell 2005;16:1543–54.

24. Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of mitochondrial dynamics in the failing heart: normalization following long-term therapy with elamipretide. Cardiovasc Drugs Ther 2018;32:319–28.

25. Shen Z, Ye C, McCann K, Greenberg ML. The role of cardiopilin in cardiovascular health. Biomed Res Int 2015;2015:891707.

26. Dolinsky VW, Cole LK, Sparagana GC, Hatch GM. Cardiac mitochondrial energy metabolism in heart failure: role of cardiopilin and sir-tuins. Biochim Biophys Acta 2016;1861:1544–54.

27. Ott M, Robertson JD, Goyvatze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A 2002;99:12569–63.

28. Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrion-targeted cardiotonics in cardiovascular diseases. World J Cardiol 2014;6:1091–9.

29. Sabbah H, Gupta RC, Rastogi S, Wang M. Dysregulation of mitochondrial fission and fusion proteins in explanted failure human hearts. J Heart Lung Transplant 2011;30(4S):S137.

30. Saini-Chohan HK, Holmes MG, Chico AJ, et al. Cardiolipin biosynthesis and remodeling enzymes are altered during development of heart failure. J Lipid Res 2009;50:1600–8.

31. Sparagana GC, Chico AJ, Murphy RC, et al. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res 2007;48:1559–68.

32. Sparagana GC, Lesniesky EJ. Cardiolipin remodeling in the heart. J Cardiovasc Pharmacol 2009;53:290–301.

33. Lai L, Leone TC, Zechner C, et al. Transcriptional coactivators PGC-1alpha and PGC-1beta control overlapping programs required for perinatal maturation of the heart. Genes Dev 2008;22:1948–61.

34. Martin OJ, Lai L, Soundarapandian MM, et al. A role for peroxisome proliferator-activated receptor gamma coactivator-1 in the control of mitochondrial dynamics during postnatal cardiac growth. Circ Res 2014;114:626–36.

35. Riehle C, Wende AR, Zaha VG, et al. PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res 2011;109:783–93.

36. Bugger H, Schwarzer M, Chen D, et al. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res 2010;85:376–84.

37. Garnier A, Fortin D, Delomeine C, Momien I, Vekler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003;551:491–501.

38. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 2006;103:10086–91.

39. Gupta RC, Szekely K, Wang M, et al. Long-term therapy with partial adenosine A1 receptor agonist capadenoson, improves peroxisome proliferators-activated receptor coactivator-1α phosphorylation and protein expression in left ventricular myocardium of dogs with chronic heart failure. J Am Coll Cardiol 2013;61:Suppl.E702.

40. Karamanidis G, Nascimben L, Cooper GS, Seale P, et al. Mitochondrial biogenesis in human failing hearts. Circ Res 2010;106:1541–8.

41. Siag S, Cresci S, Li AY, Sucharov CC, Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 2006;103:10086–91.

42. Gottlieb RA, Bernstein D. Mitochondrial dysfunction in heart failure: role of cardiolipin and sir-tuins. Biochim Biophys Acta 2015;21:273–83.

43. ferrans VJ, Morrow AG, Roberts WC. Myocardial ultrastructure in idiopathic hypertrophic subaortic stenosis: a study of operatively excised left ventricular outflow tract muscle in 14 patients. Circulation 1972;45:769–92.

44. Ott M, Robertson JD, Goyvatze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A 2002;99:12569–63.

45. Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrion-targeted cardiotonics in cardiovascular diseases. World J Cardiol 2014;6:1091–9.

46. Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of mitochondrial dynamics in the failing heart: normalization following long-term therapy with elamipretide. Cardiovasc Drugs Ther 2018;32:319–28.

47. Shen Z, Ye C, McCann K, Greenberg ML. The role of cardiopilin in cardiovascular health. Biomed Res Int 2015;2015:891707.

48. Dolinsky VW, Cole LK, Sparagana GC, Hatch GM. Cardiac mitochondrial energy metabolism in heart failure: role of cardiopilin and sir-tuins. Biochim Biophys Acta 2016;1861:1544–54.

49. Ott M, Robertson JD, Goyvatze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A 2002;99:12569–63.

50. Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrion-targeted cardiotonics in cardiovascular diseases. World J Cardiol 2014;6:1091–9.

51. Sabbah H, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of mitochondrial dynamics in the failing heart: normalization following long-term therapy with elamipretide. Cardiovasc Drugs Ther 2018;32:319–28.

52. Shen Z, Ye C, McCann K, Greenberg ML. The role of cardiopilin in cardiovascular health. Biomed Res Int 2015;2015:891707.

53. Dolinsky VW, Cole LK, Sparagana GC, Hatch GM. Cardiac mitochondrial energy metabolism in heart failure: role of cardiopilin and sir-tuins. Biochim Biophys Acta 2016;1861:1544–54.

54. Ott M, Robertson JD, Goyvatze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A 2002;99:12569–63.

55. Ajith TA, Jayakumar TG. Mitochondria-targeted agents: future perspectives of mitochondrion-targeted cardiotonics in cardiovascular diseases. World J Cardiol 2014;6:1091–9.

56. Sabbah HN, Gupta RC, Singh-Gupta V, Zhang K, Lanfear DE. Abnormalities of mitochondrial dynamics in the failing heart: normalization following long-term therapy with elamipretide. Cardiovasc Drugs Ther 2018;32:319–28.

57. Shen Z, Ye C, McCann K, Greenberg ML. The role of cardiopilin in cardiovascular health. Biomed Res Int 2015;2015:891707.
Targeting Mitochondria in Heart Failure

108. Ji LL, Kang C. Role of PGC-1alpha in sarcopenia: etiology and potential intervention—a mini-review. Gerontology 2015;61:139-48.

109. Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell 2008;7:2-12.

110. Ghosh S, Lertwattanarak R, Lefort N, et al. Reduction in reactive oxygen species production by mitochondria from elderly subjects with normal and impaired glucose tolerance. Diabetes 2011;60:2051-60.

111. Cuervo AM, Bergamini E, Brunk UT, Bergamini E, Brunk UT, Droge W, Cuervo AM, Bergamini E, Brunk UT, Droge W, saleem A, Hood DA. Mitochondrial function and oxidative stress. The mitochondrial-lysosomal axis theory of aging: accumulation of dysfunctional mitochondria due to oxidative stress. Aging Cell 2008;7:2-12.

112. Coleman R, Silbermann M, Gershon D, Reznick AZ. Giant mitochondria in the myocardium of aging and endurance-trained mice. Gerontology 2015;61:139-48.

113. Brunk UT, Terman A. Autophagy and aging: the importance of maintaining "clean" cells. Autophagy 2005;1:31-40.

114. Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther 2014;96:672-83.

115. Luevano-Martinez LA, Forni MF, dos Santos VT, Souza-Pinto NC, Kowaltowski AJ. Cardiolipin is a key determinant for mtDNA stability and segregation during mitochondrial stress. Biochim Biophys Acta 2015;1847:587-98.

116. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013;24:1250-61.

117. Chatfield KC, Sparagna GC, Chau S, et al. Elamipretide improved mitochondrial function in the failing human heart. J Am Coll Cardiol Basic Trans Science 2019;4:147-57.

118. Daubert MA, Yow E, Dunn G, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail 2017;10. pii: e003489.

119. Greene SJ, Sabbah HN, Butler J, et al. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev 2016;21:95-102.

120. Mustafa SJ, Morrison RR, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Pharmacol 2009;193:161-88.

121. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005;67:1385-7.

122. Akbar M, Okajima F, Tomura H, Shimegi S, Kondo Y. A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release. Mol Pharmacol 1994;45:1036-42.

123. Yuan K, Cao C, Han JH, Kim SZ, Kim SH. Adenosine-stimulated atrial natriuretic peptide release through A1 receptor subtype. Hypertension 2005;46:1381-7.

124. Schutte F, Burgdorf C, Richardt G, Kurz T. Adenosine A1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase. Can J Physiol Pharmacol 2006;84:573-7.

125. Xiang F, Huang YS, Zhang DX, Chu ZG, Zhang JP, Zhang Q. Adenosine A1 receptor activation reduces opening of mitochondrial permeability transition pores in hypoxic cardiac myocytes. Clin Exp Pharmacol Physiol 2010;37:343-9.

126. Puhl SL, Kazakov A, Muller A, et al. Adenosine A1 receptor activation attenuates cardiac hypertrophy and fibrosis in response to alpha1-adrenergic receptor stimulation in vivo. Br J Pharmacol 2016;173:88-102.

127. Fredholm BB, AB PJ, Jacobson KA, Klots KN, Linden J. International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.e6.

128. Dinh W, Albrecht-Kupper B, Gheorghiea M, Voors AA, van der Laan M, Sabbah HN. Partial adenosine A1 agonist in heart failure. Handb Exp Pharmacol 2017;243:177-203.

129. Albrecht-Kupper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal 2012;8:91-9.

130. Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 2013;6:563-71.

131. Tendera M, Gaszewska-Zurek E, Parma Z, et al. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 2012;101:585-91.

132. Meibom O, Albrecht-Kupper B, Diedrichs N, et al. Neladenoson bialanate hydrochloride: a produg of a partial adenosine A1 receptor agonist for the chronic treatment of heart diseases. ChemMedChem 2017;12:728-37.

133. Voors AA, Dungen HD, Senni M, et al. Safety and tolerability of neladenoson bialanate, a novel oral partial adenosine A1 receptor agonist, in patients with chronic heart failure. J Clin Pharmacol 2017;57:440-51.

134. Voors AA, Shah SJ, Bax JJ, et al. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. Eur J Heart Fail 2018;20:1601-10.

KEY WORDS: cardiolipin, heart failure, mitochondria, myocardial energetics, oxidative phosphorylation.